Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy

American Journal of Health-System Pharmacy

Volumn 70, Issue 4, 2013, Pages 343-349

  Uchida, Mayako ^a   Ikesue, Hiroaki ^a   Kato, Koji ^b   Ichinose, Kimiko ^c   Hiraiwa, Hiromi ^c   Sakurai, Asako ^c   Takenaka, Katsuto ^b   Iwasaki, Hiromi ^b   Miyamoto, Toshihiro ^b   Teshima, Takanori ^b   Egashira, Nobuaki ^a   Akashi, Koichi ^b   Oishi, Ryozo ^d  

^a KYUSHU UNIVERSITY HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KUH   (Japan)

^d KUH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANISETRON; IDARUBICIN; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE SULFATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG RESPONSE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FEMALE; FLUSHING; HEADACHE; HEMATOLOGIC MALIGNANCY; HICCUP; HUMAN; HYPERSENSITIVITY; INSOMNIA; LYMPHOMA; MALAISE; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; UNIVERSITY HOSPITAL;

EID: 84874041940     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120363     Document Type: Article

References (38)

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008; 358:2482-94.
2. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21(suppl 5): v232-43.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis. V.1.2012. www.nccn.org/professionals/physician-gls/pdf/ antiemesis.pdf (accessed 2012 May 16).
4. Einhorn LH, Grunberg SM, Rapoport B et al. Antiemetic therapy for multipleday chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement. Support Care Cancer. 2011; 19(suppl 1):S1-4.
5. Handberg J, Wessel V, Larsen L et al. Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapy. Support Care Cancer. 1998; 6:63-7.
6. Forni C, Ferrari S, Loro L et al. Granisetron, tropisetron, and ondansetron in the prevention of acute emesis induced by a combination of cisplatin-Adriamycin and by high-dose ifosfamide delivered in multiple-day continuous infusions. Support Care Cancer. 2000; 8:131-3.
7. Einhorn LH, Brames MJ, Dreicer R et al. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support Care Cancer. 2007; 15:1293-300.
8. Boccia RV, Gordan LN, Clark G et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011; 19:1609-17.
9. Feinberg B, Gilmore J, Haislip S. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. Support Care Cancer. 2012; 20:615-23.
10. Braken JB, Raemaekers JM, Koopmans PP et al. Control of nausea and vomiting with ondansetron in patients treated with intensive non-cisplatin chemotherapy for acute myeloid leukaemia. Eur J Cancer. 1993; 29A:515-8.
11. López-Jiménez J, Martín-Ballesteros E, Sureda A et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. Haematologica. 2006; 91:84-91.
12. Musso M, Scalone R, Bonanno V et al. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple day chemotherapy. Support Care Cancer. 2009; 17:205-9.
13. Mattiuzzi GN, Cortes JE, Blamble DA et al. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer. 2010; 116:5659-66.
14. De Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatinbased chemotherapy. J Clin Oncol. 2003; 21:4105-11.
15. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003; 97:3090-8.
16. Gralla RJ, de Wit R, Herrstedt J et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomized clinical trials. Cancer. 2005; 104:864-8.
17. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23:2822-30.
18. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, doubleblind study. Support Care Cancer. 2010; 18:423-31.
19. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29:4189-98.
20. Jordan K, Kinitz I, Voigt W et al. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer. 2009; 45:1184-7.
21. Jordan K, Jahn F, Jahn P et al. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011; 46:784-9.
22. Gao H, Liang Y, Zhou N et al. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin-based chemotherapy. Intern Med J. Epub ahead of print. 2011 Dec 5 (DOI 10.1111/j.1445-5994.2011.02637.x).
23. Paul B, Trovato JA, Thompson J et al. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract. 2010; 16:45-51.
24. Stiff P, Fox-Geiman M, Kiley K et al. Aprepitant vs. placebo plus oral ondansetron and dexamethasone for the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to hematopoietic stem cell transplantation: a prospective, randomized double-blind phase III trial. Blood. 2009; 114:2267. Abstract.
25. Majumdar AK, McCrea JB, Panebianco DL et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 2003; 74:150-6.
26. Georgy A, Neceskas J, Goodin S. Antiemetic care for patients with breast cancer: focus on drug interactions and safety concerns. Am J Health-Syst Pharm. 2007; 64:2227-36.
27. Aapro MS, Walko CM. Aprepitant: drugdrug interactions in perspective. Ann Oncol. 2010; 21:2316-23.
28. Larson RA, Dodge RK, Burns CP et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995; 85:2025-37.
29. Velasquez WS, McLaughlin P, Tucker S et al. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994; 12:1169-76.
30. Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005; 23:7013-23.
31. Emend (aprepitant) package insert. Whitehouse Station, NJ: Merck; 2011 Mar.
32. National Cancer Institute. Common terminology criteria for adverse events (CTCAE), version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14- QuickReference-8.5x11.pdf (accessed 2012 Sep 11).
33. Eastern Cooperative Oncology Group. ECOG performance status. www.ecog.org/general/perf-stat.html (accessed 2012 Sep 11).
34. Shadle CR, Lee Y, Majumdar AK et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004; 44:215-23.
35. Walko CM, Combest AJ, Spasojevic I et al. The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients. Cancer Chemother Pharmacol. 2012; 69:1189-96.
36. Bubalo JS, Cherala G, McCune JS et al. Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol. 2012; 52:586-94.
37. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003; 21:4112-9.
38. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23:2822-30.